Released on: March 19, 2008, 8:18 am

Press Release Author: Biotage

Industry:

Press Release Summary: Biotage, a leading supplier of tools and technology for
medicinal and analytical chemistry, announces the introduction of the new Advancer®
Kilobatch large-scale automated sequential batch microwave synthesizer. This new
system is designed for safe and scalable production of up to kilogram quantities of
material and will be showcased exclusively on booth #1611 at ACS Spring 2008, New
Orleans.



Press Release Body: News release
Contact:
Jennifer Whedbee, Director Marketing Communications
Tel: +1 434 220 2652, jwhedbee@biotage.com

Biotage Introduces the New Advancer® Kilobatch for Automated Batch Sequencing at ACS
Spring 2008

(March 19, 2008) Biotage, a leading supplier of tools and technology for medicinal
and analytical chemistry, announces the introduction of the new Advancer® Kilobatch
large-scale automated sequential batch microwave synthesizer. This new system is
designed for safe and scalable production of up to kilogram quantities of material
and will be showcased exclusively on booth #1611 at ACS Spring 2008, New Orleans.

The Advancer Kilobatch from Biotage is designed to address fast and reliable
microwave scale-up without requiring re-optimization, resulting in significant time
savings for users. Unlike traditional microwave batch and flow reactors, the
Advancer Kilobatch is capable of processing both heterogeneous and homogenous
reaction mixtures in automated batch-sequencing mode. Safe, reliable and easy to
use, the Advancer Kilobatch operates at the high temperatures and pressures required
for microwave chemistry.

Also presented on booth #1611 will be the latest ranges of SNAP cartridges from
Biotage. The unique KP-NH SNAP cartridges are designed to purify organic amine
reaction mixtures by flash purification. The innovative KP-NH chemistry shields
organic amines from silanols, improving separations while eliminating the need for
DCM and competing amines in gradients. The new SNAP KP-C18-HS from Biotage are
reversed-phase flash cartridges designed to provide high sample-load purification of
polar and ionizable compounds. Unlike conventional amino cartridges, both the SNAP
KP-NH and the SNAP KP-C18-HS from Biotage offer seven sample loading options
including internal dry loading with and without Samplet cartridges.

Biotage will also demonstrate the latest addition to the innovative EVOLUTE® sample
preparation range on booth #1611. EVOLUTE CX is a mixed-mode resin-based SPE sorbent
for the extraction of basic drugs from biological fluids using a generic procedure,
minimizing method development time for bioanalysts. EVOLUTE CX removes protein,
phospholipids, and salt interferences, delivering cleaner extracts with high
reproducibility for accurate quantitation and trouble-free analyses through
pre-clinical and clinical trials.

For more information on Biotage's EVOLUTE CX sample preparation products, please
visit booth #1611 at ACS Spring 2008, from 6-10 April 2008. Alternatively please
email product_info@biotage.com or visit www.biotage.com

-ENDS-
For further press information please contact: Eleanor CallanMonk, The Scott
Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44
1477 539539 Fax: +44 1477 539540 e-mail: biotage@scottpr.com

About Biotage
Biotage is a global company active in life science research with strong
technologies, a broad range of operations and a long-term view of the market. The
company offers solutions, knowledge and experience in the areas of genetic analysis
and medicinal chemistry. In 2005 operations and products were acquired from the
American company Argonaut, further strengthening the medicinal chemistry product
range. The customers include the worlds top 30 pharmaceutical companies, the worlds
top 20 biotech companies, and leading academic institutes. The company is
headquartered in Uppsala and has offices in the U.S., Japan, UK, Germany and several
other European countries. Biotage has 336 employees and had sales of 496,4 MSEK in
2007. Biotage is listed on the OMX Nordic Exchange Stockholm AB. Website:
www.biotage.com

Certain statements in this press release are forward-looking. These may be
identified by the use of forward-looking words or phrases such as \"believe,\"
\"expect,\" \"intend,\" and \"should,\" among others. These forward-looking statements are
based on Biotage's current expectations. The Private Securities Litigation Reform
Act of 1995 provides a \"safe harbor\" for such forward-looking statements. In order
to comply with the terms of the safe harbor, Biotage notes that a variety of factors
could cause actual results and experience to differ materially from the anticipated
results or other expectations expressed in such forward-looking statements. Such
uncertainties and risks include, but are not limited to, risks associated with
management of growth and international operations (including the effects of currency
fluctuations), variability of operating results, the commercial development of the
microwave synthesis and flash purification in the drug discovery market, DNA
sequencing and genomics market, nucleic acid-based molecular diagnostics market, and
genetic vaccination and gene therapy markets, competition, rapid or unexpected
changes in technologies, fluctuations in demand for Biotage's products (including
seasonal fluctuations), difficulties in successfully adapting the Company's products
to integrated solutions and producing such products, and the Company's ability to
identify and develop new products and to differentiate its products from
competitors.

Web Site: http://

Contact Details: THE SCOTT PARTNERSHIP
1 WHITESIDE
STATION ROAD
HOLMES CHAPEL
CHESHIRE
CW5 5GJ
UK
01477 539539
biotage@scottpr.com